|
 |
AmerisourceBergen: Leonardo DeCandia, Senior Vice President, Supply Chain Management |
 |
|
| |
Atmel: Todd Whitford, RFID Specialist |
 |
|
 |
Baxter Healthcare Corporation: J. Andrew Harrison, Esq., Senior Manager, Global Regulatory Affairs & Pharmacovigilance |
 |
|
 |
California State Board of Pharmacy: Judith Nurse, Supervising Inspector |
 |
|
 |
Carr Maloney P.C., Paul J.Maloney, Member |
 |
Paul Maloney, a Member of the firm, concentrates his practice on product liability and commercial litigation. He has often represented corporations in the life science industry, to include the defense of pharmaceutical product integrity. He filed an amicus briefs in the Supreme Court in Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), and in Riegel v. Medtronic, Inc., Docket No. 06-179 (2007), the two leading medical device cases on the issue of federal preemption. The Riegel decision is expected in the spring of 2008. Paul has written on products liability legislation pending before Congress and on the product misuse defense available in products liability litigation.
Before joining the firm in 1984, Paul served as a law clerk to the Hon. Joseph M. Hannon, Superior Court Judge for the District of Columbia. Following his clerkship, Paul served as an Assistant State’s Attorney for Prince George’s County, Maryland. In 1987, he was appointed Associate Independent Counsel to James C. McKay in the Lynn Nofziger Investigation. |
|
| |
Center for Medicine In The Public Interest (CMPI): Peter Pitts, President |
 |
|
| |
Drug Enforcement Administration, Headquarters: Philippa LeVine, Special Agent, Office of Enforcement Operations, Dangerous Drugs and Chemicals Section |
 |
Special Agent Philippa LeVine began her career with DEA in 1983 and was assigned to the San Diego Field Division. During her tenure in the SDFD, S/A LeVine was assigned to the Clandestine Laboratory Group and was involved in approximately 175 clandestine methamphetamine laboratory investigations, and also assumed an undercover role in countless of other cases. In 1986 she was the case agent on a high profile investigation that brought attention to the role precursor chemicals have in the production of methamphetamine. Due to the steady press attention at the culmination of this case, the State of California initiated new laws regarding listed precursor chemicals. Subsequently, several other states followed California’s lead, and eventually the federal law was also reformed.
In 1989, S/A LeVine was assigned to the San Diego Narcotic Task Force serving with other federal, state and local law enforcement officers in investigating international drug trafficking organizations. In 1994 S/A LeVine was assigned to the asset forfeiture/ money laundering group, conducted several long term money laundering investigations, and was promoted to the Group Supervisor in 1999.
In 2002, S/A LeVine transferred to the Office of Enforcement Operations, Dangerous Drug and Chemicals Section in DEA Headquarters in Arlington VA. S/A LeVine assisted in changing the Federal Sentencing Guidelines for steroids and GHB and its analogues. Additionally, S/A LeVine has briefed Ambassadors, Senate staffers, international delegations and given presentations on synthetic drugs to law enforcement, pharmaceutical industry, educational and civic organizations. In this headquarters capacity, S/A LeVine also coordinates and directs highly sensitive domestic and international synthetic drug investigations leading to the arrest, prosecution and dismantling of the drug trafficking organizations. |
|
|
Health Industry Distributors Association (HIDA): Andrew Van Ostrand, Vice President, Policy and Research |
|
|
 |
Henry Schein, Inc.: Brian Jude Loiacono, Senior Regulatory Specialist |
 |
| Brian Loiacono holds a BA; Degree from Dowling College and an MS; Degree from New York Institute of Technology. Brian came to Henry Schein in February 2004 working for their Private Label Division in the Quality Assurance area. In July of 2005, Brian joined the Regulatory Affairs Department where he monitors and analyzes on a daily basis all relevant state and federal legislations and its impact to wholesale distributors. Further, he conducts ISO, Due Diligence or GAP analysis audits for the company; where such audits normally identify and emphasize regulatory risks and quality managements systems. Brian is passionate about developing relationships with key governmental agencies so that his guidance can help his company continue to meet regulatory compliance in a very complex environment. |
|
 |
H. D. Smith: Ron Lanton III, J.D., Industry Analyst |
 |
|
 |
Indiana University Hospital: Donna Wall, Clinical Pharmacist, Adult Critical Care, Clarian Health Partners, Board Mem |